Literature DB >> 31005229

Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.

Christopher L Tinkle1, Noelle L Williams2, Huiyun Wu3, Jianrong Wu4, Sue C Kaste5, Barry L Shulkin6, Aimee C Talleur7, Jamie E Flerlage8, Melissa M Hudson8, Monika L Metzger8, Matthew J Krasin9.   

Abstract

BACKGROUND AND
PURPOSE: The use of radiotherapy (RT) for pediatric patients with Hodgkin lymphoma (HL) experiencing disease progression or recurrence (15%) is controversial. We report treatment patterns and outcomes for pediatric patients with refractory/recurrent HL (rrHL) treated with curative-intent RT.
MATERIALS AND METHODS: Forty-six patients with rrHL treated with salvage RT at our institution were identified. All received risk-adapted, response-based frontline therapy and were retrieved with cytoreductive regimens followed by RT to failure sites, with or without autologous hematopoietic cell transplantation (AHCT). Cumulative incidence (CIN) of local failure (LF) and survival were estimated after salvage RT and regression models determined predictors of LF after salvage RT.
RESULTS: RT was administered as part of frontline therapy in 70% of patients, omitted for early response assessment in 13%, or deferred for primary progression in 17%. AHCT was omitted in 20% of patients. Median initial and salvage dose/site were 25.5 Gy and 30.6 Gy, respectively. Eight patients experienced progression. Two died without progression (median follow-up from salvage RT = 3.8 years). The 5-year CIN of LF after salvage RT was 17.7% (95% confidence interval [CI], 8.2-30.2%). The 5-year freedom from subsequent treatment failure and overall survival (OS) was 80.1% (95% CI, 69.2-92.6%) and 88.5% (95% CI, 79.5-98.6%), respectively. Inadequate response to salvage systemic therapy (p = 0.048) and male sex (p = 0.049) were significantly associated with LF after salvage RT.
CONCLUSION: rrHL is responsive to salvage RT, with low LF rates after moderate doses. OS is excellent, despite refractory disease. Initial salvage therapy response predicts subsequent LF. Published by Elsevier B.V.

Entities:  

Keywords:  Hodgkin lymphoma; Local failure; Pediatric; Radiation therapy; Recurrent; Relapsed

Mesh:

Year:  2019        PMID: 31005229      PMCID: PMC6478442          DOI: 10.1016/j.radonc.2019.01.026

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  45 in total

1.  Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Robert Chen; Joycelynne M Palmer; Sandra H Thomas; Ni-Chun Tsai; Len Farol; Auayporn Nademanee; Stephen J Forman; Ajay K Gopal
Journal:  Blood       Date:  2012-05-18       Impact factor: 22.113

2.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

3.  Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients.

Authors:  Monika L Metzger; Melissa M Hudson; Matthew J Krasin; Jianrong Wu; Sue C Kaste; Larry E Kun; John T Sandlund; Scott C Howard
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

4.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

5.  Salvage radiotherapy in recurrent Hodgkin's disease.

Authors:  M Brada; R Eeles; S Ashley; J Nichols; A Horwich
Journal:  Ann Oncol       Date:  1992-02       Impact factor: 32.976

6.  Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).

Authors:  Stéphanie Gorde-Grosjean; Odile Oberlin; Thierry Leblanc; Hélène Pacquement; Jean Donadieu; Anne Lambilliotte; Mathias Schell; Florence Dommange; Martine Munzer; Catherine Paillard; Claudine Schmitt; Patrick Lutz; Christine Edan; Sophie Ansoborlo; Jean-Louis Stephan; Gérard Michel; Caroline Thomas; Yves Perel; Alain Robert; Judith Landman-Parker
Journal:  Br J Haematol       Date:  2012-07-04       Impact factor: 6.998

7.  Radiation therapy salvage of Hodgkin's disease following chemotherapy failure.

Authors:  K A Fox; S M Lippman; J R Cassady; R S Heusinkveld; T P Miller
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

8.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Authors:  D Hasenclever; V Diehl
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck.

Authors:  X Panis; P Coninx; T D Nguyen; M Legros
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-06       Impact factor: 7.038

10.  Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease.

Authors:  Sara Stoneham; Sue Ashley; C Ross Pinkerton; W Hamish Wallace; Ananth Gouri Shankar
Journal:  J Pediatr Hematol Oncol       Date:  2004-11       Impact factor: 1.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.